What is the appropriate management for an acute abscess in hidradenitis suppurativa?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Management of Acute Abscess in Hidradenitis Suppurativa

Incision and drainage should be used ONLY for acute abscesses to provide immediate pain relief, but it is NOT a definitive treatment and carries high recurrence risk 1.

Immediate Abscess Management

For an acute, painful abscess in HS, the primary goal is pain relief through drainage. However, this must be understood as a temporizing measure, not curative therapy 1. The key distinction from simple skin abscesses is that HS abscesses arise from chronic follicular occlusion and inflammation, not primary bacterial infection.

Critical Pitfall to Avoid

Do NOT treat HS abscesses with incision and drainage alone as if they were simple furuncles. This is the most common management error and leads to rapid recurrence because it fails to address the underlying inflammatory disease 2, 3.

Comprehensive Acute Management Algorithm

Step 1: Immediate Pain Control and Drainage (if needed)

  • Perform incision and drainage ONLY if the abscess is fluctuant and causing severe pain
  • This provides symptomatic relief but expect recurrence without additional therapy 1
  • Consider intralesional triamcinolone (10-40 mg/mL) for acute inflammatory nodules that are not yet fluctuant 4

Step 2: Initiate Medical Therapy Immediately

All patients with HS abscesses require concurrent medical therapy 5:

For mild disease (isolated abscess, Hurley Stage I):

  • Start topical clindamycin 1% solution/gel twice daily for 12 weeks 5
  • OR oral tetracycline 500 mg twice daily for 4 months 5

For moderate-to-severe disease (multiple abscesses, recurrent, or Hurley Stage II-III):

  • Start oral clindamycin 300 mg twice daily PLUS rifampin 600 mg once daily for 10 weeks 5
  • This combination targets both the inflammatory component and secondary bacterial colonization

Step 3: Adjuvant Therapy (Start Immediately)

All patients must receive 5:

  • Pain management (NSAIDs, acetaminophen, or opioids for severe pain)
  • Appropriate wound dressings based on drainage amount
  • Antiseptic washes (chlorhexidine or benzoyl peroxide) 4
  • Tobacco cessation counseling (smoking worsens disease)
  • Weight loss counseling if BMI >25 (obesity is a major risk factor)

Step 4: Assess for Escalation

If the patient fails to improve within 2-4 weeks or has moderate-to-severe disease at presentation:

  • Escalate to adalimumab: 160 mg at week 0,80 mg at week 2, then 40 mg subcutaneously weekly 5
  • This is the only FDA-approved biologic with Level Ib evidence (Strength of Recommendation A) 5
  • Continue medical therapy during the biologic loading period

Step 5: Surgical Planning

Assess for definitive surgical intervention 1:

  • Wide local excision is appropriate for chronic, recurrent abscesses with sinus tract formation
  • Surgery should be planned electively, NOT during acute flare
  • Continue medical therapy perioperatively - evidence suggests this improves outcomes and does not increase complications 1
  • Reconstruction options include secondary intention healing, primary closure, flaps, or grafts depending on defect size 1

Evidence Strength and Nuances

The 2016 European guidelines 5 provide the most comprehensive evidence-based framework, though they acknowledge limited high-quality data. The 2019 North American guidelines 1, 4 specifically emphasize that incision and drainage is a poor standalone treatment. The most recent 2025 guidelines 6 focus on special populations but reinforce the same core principles.

Key evidence hierarchy:

  • Adalimumab has the strongest evidence (LOE Ib, SOR A) for moderate-to-severe disease 5
  • Clindamycin-rifampin combination has moderate evidence (LOE III, SOR C) 5
  • Topical clindamycin and tetracyclines have fair evidence (LOE IIb, SOR B) 5
  • Incision and drainage is supported only by expert consensus for pain relief, not disease control 1

Special Considerations

Pregnancy: Intralesional steroids, topical clindamycin, cephalexin, azithromycin, and clindamycin are considered safe 6. Avoid tetracyclines and rifampin (though rifampin is used for TB in pregnancy, data for HS are lacking) 6.

Superinfection: If purulent drainage with systemic signs (fever, elevated WBC), add coverage for Staphylococcus aureus and gram-negative organisms 5. Consider wound culture to guide therapy.

Pain management: HS pain is often undertreated. Use multimodal analgesia and consider referral to pain management for chronic cases 5.

Bottom Line Treatment Pathway

  1. Drain if fluctuant (pain relief only)
  2. Start antibiotics immediately (clindamycin-rifampin for moderate-severe)
  3. Add adjuvant therapy (pain control, wound care, lifestyle modification)
  4. Escalate to adalimumab if inadequate response in 2-4 weeks
  5. Plan definitive surgery for chronic disease with continued medical therapy

This approach addresses both the acute inflammatory crisis and the chronic underlying disease, which is essential for preventing the cycle of recurrent abscesses that devastates quality of life in HS patients.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.